Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy.

Scientific reports - 28 Dec 2024

Ben Kacem Mariam, Bright Scott J, Moran Emma, Flint David B, Martinus David K J, Turner Broderick X, Qureshi Ilsa, Kolachina Rishab, Manandhar Mandira, Marinello Poliana C, Shaitelman Simona F, Sawakuchi Gabriel O

Abstract excerpt

Aggressive breast cancers often fail or acquire resistance to radiotherapy. To develop new strategies to improve the outcome of aggressive breast cancer patients, we studied how PARP inhibition radiosensitizes breast cancer models to proton therapy, which is a radiotherapy modality that generates more DNA damage in the tumor than standard radiotherapy using photons. Two human BRCA1-mutated breast cancer cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to DNA Damage

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Radiation-Sensitizing Agents

Share to Radiation Tolerance

Source

Open in PubMed Open full text

Identifiers

PMID: 39730675
DOI: 10.1038/s41598-024-81914-w
PMCID: PMC11680706

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy.PMID 39730675Read ↗

Therapeutic potential of PARP inhibitors for metastatic breast cancerSemantic proximity Read ↗

Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and ProtonsSemantic proximity Read ↗

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor ResponseSemantic proximity Read ↗

PARP inhibitors combined with radiotherapy: are we ready?Semantic proximity Read ↗

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation TherapySemantic proximity Read ↗

The Radiobiological Effects of Proton Beam Therapy: Impact on DNA Damage and RepairSemantic proximity Read ↗

CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cellsSemantic proximity Read ↗

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermiaSemantic proximity Read ↗

Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiationSemantic proximity Read ↗

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic ProbesSemantic proximity Read ↗

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor MicroenvironmentSemantic proximity Read ↗

Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-iSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.